Amphastar Pharmaceuticals Inc. (AMPH) Trading 2.3% Higher
Amphastar Pharmaceuticals Inc. (NASDAQ:AMPH)’s share price traded up 2.3% during trading on Wednesday . The company traded as high as $18.49 and last traded at $18.33, with a volume of 132,168 shares traded. The stock had previously closed at $17.91.
A number of equities analysts have recently commented on the company. Piper Jaffray Cos. reissued an “overweight” rating and set a $22.00 price target on shares of Amphastar Pharmaceuticals in a report on Thursday, August 11th. Jefferies Group boosted their price target on Amphastar Pharmaceuticals from $16.00 to $19.00 and gave the stock a “buy” rating in a report on Tuesday, August 9th. BMO Capital Markets reissued a “hold” rating and set a $17.00 price target on shares of Amphastar Pharmaceuticals in a report on Tuesday, August 9th. Zacks Investment Research raised Amphastar Pharmaceuticals from a “hold” rating to a “buy” rating and set a $18.00 price target for the company in a report on Monday, August 1st. Finally, Needham & Company LLC boosted their price target on Amphastar Pharmaceuticals from $20.00 to $22.00 and gave the stock a “buy” rating in a report on Tuesday, August 9th. Two analysts have rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the stock. Amphastar Pharmaceuticals has a consensus rating of “Buy” and a consensus target price of $20.00.
The stock has a market cap of $822.56 million, a price-to-earnings ratio of 59.19 and a beta of 1.83. The firm has a 50 day moving average price of $18.19 and a 200 day moving average price of $15.08.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/14/amphastar-pharmaceuticals-inc-amph-trading-2-3-higher.html
Amphastar Pharmaceuticals (NASDAQ:AMPH) last posted its earnings results on Monday, August 8th. The company reported $0.23 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.01 by $0.22. The company had revenue of $68 million for the quarter, compared to analysts’ expectations of $62.10 million. Amphastar Pharmaceuticals had a return on equity of 4.71% and a net margin of 5.19%. Amphastar Pharmaceuticals’s quarterly revenue was up 26.4% on a year-over-year basis. During the same period last year, the firm earned ($0.09) earnings per share. Equities research analysts forecast that Amphastar Pharmaceuticals Inc. will post $0.37 earnings per share for the current fiscal year.
In related news, Director Floyd F. Petersen sold 3,000 shares of the firm’s stock in a transaction dated Thursday, September 8th. The stock was sold at an average price of $19.05, for a total value of $57,150.00. Following the sale, the director now directly owns 60,317 shares of the company’s stock, valued at $1,149,038.85. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Diane G. Gerst sold 24,046 shares of Amphastar Pharmaceuticals stock in a transaction that occurred on Friday, August 19th. The shares were sold at an average price of $19.28, for a total value of $463,606.88. Following the sale, the executive vice president now directly owns 39,031 shares in the company, valued at $752,517.68. The disclosure for this sale can be found here. 29.30% of the stock is owned by corporate insiders.
Hedge funds have recently bought and sold shares of the stock. Acrospire Investment Management LLC boosted its stake in Amphastar Pharmaceuticals by 57.5% in the second quarter. Acrospire Investment Management LLC now owns 6,791 shares of the company’s stock valued at $109,000 after buying an additional 2,479 shares during the last quarter. Envestnet Asset Management Inc. purchased a new stake in Amphastar Pharmaceuticals during the first quarter valued at $115,000. BlackRock Group LTD boosted its stake in Amphastar Pharmaceuticals by 61.7% in the first quarter. BlackRock Group LTD now owns 11,629 shares of the company’s stock valued at $140,000 after buying an additional 4,439 shares during the last quarter. Los Angeles Capital Management & Equity Research Inc. purchased a new stake in Amphastar Pharmaceuticals during the first quarter valued at $180,000. Finally, C M Bidwell & Associates Ltd. purchased a new stake in Amphastar Pharmaceuticals during the second quarter valued at $207,000. 35.87% of the stock is currently owned by institutional investors and hedge funds.
About Amphastar Pharmaceuticals
Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses primarily on developing, manufacturing, marketing and selling generic and injectable and inhalation products. The Company has two segments: finished pharmaceutical products and active pharmaceutical ingredients (API) products.
Receive News & Ratings for Amphastar Pharmaceuticals Inc. Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Amphastar Pharmaceuticals Inc. and related companies with MarketBeat.com’s FREE daily email newsletter.